Literature DB >> 7625986

Clinical features and differential diagnosis of pituitary tumours with emphasis on acromegaly.

J V Hennessey1, I M Jackson.   

Abstract

Pituitary adenomas are frequently encountered, benign intracranial tumours. Clinically classified according to their capacity to produce and secrete hormones, pituitary tumours are diagnosed from the clinical manifestations and biochemical findings of specific pituitary hormone overproduction or of impaired pituitary function due to pressure on normal pituitary cells, the pituitary stalk or the hypothalamus. Additionally, the tumour may result in neurological manifestations due to its effect as an intracranial space-occupying lesion. Pituitary adenomas may present acutely with pituitary apoplexy after intrapituitary haemorrhage or infarction. The subsequent hypofunction of the pituitary with concomitant neurological sequelae of an expanding intracranial mass are often associated with excruciating headache, diplopia and visual field defects. Gradually developing neurological deficits or secondary endocrine failure over several years may precede the recognition of non-secretory tumours (30-40% of pituitary adenomas) as well as some of the hormone-producing adenomas, especially when they expand beyond the confines of the sella turcica. Asymptomatic masses occur in the pituitary in 5-27% of unselected autopsy series. About 10-20% of pituitaries imaged as part of a brain study contain lesions 'consistent with a pituitary adenoma', with about half being pituitary adenomas ('incidentalomas'). Many advocate screening such cases for a wide spectrum of pituitary function abnormalities. Clinical judgement should be utilized to determine the extent of the work-up and the frequency of follow-up. Acromegaly, a clinical syndrome caused by excess growth hormone secretion, accounts for one-sixth of resected pituitary tumours. This disorder leads to chronic progressive disability and a shortened life span, with approximately 50% of untreated acromegalic patients experiencing premature death. The prevalence of acromegaly has been estimated to range from 50 to 70 per million, with the age of diagnosis usually between the third and fifth decades. Conditions associated with acromegaly include glucose intolerance, diabetes mellitus, lipid abnormalities, cholelithiasis, goitre, and hyperthyroidism, respiratory complications, hypertension, cardiovascular disease, and calcium metabolism abnormalities. An association between acromegaly and cancer, especially of the colon, is now recognized. Epidemiological series have indicated that cancer of the colon, breast and other types of malignancy are a cause of death with increased frequency in acromegalics compared with expected rates. Hypopituitary symptoms secondary to the mass effect of macroadenomas in acromegalic patients are common. Among premenopausal women, menstrual irregularities and galactorrhoea have been reported in 40-70%, while more than half of the men complain of impotence and decreased libido.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7625986     DOI: 10.1016/s0950-351x(95)80338-6

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  9 in total

Review 1.  Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.

Authors:  Reshma Shah; Angelo Licata; Nelson M Oyesiku; Adriana G Ioachimescu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  The association between calcitonin gene-related peptide (CGRP), substance P and headache in pituitary tumours.

Authors:  M J Levy; J D Classey; S Maneesri; K Meeran; M Powell; P J Goadsby
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 3.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064

5.  Visual field defects in 23 acromegalic patients.

Authors:  Emrah Kan; Elif Kilic Kan; Aysegul Atmaca; Hulusi Atmaca; Ramis Colak
Journal:  Int Ophthalmol       Date:  2013-02-09       Impact factor: 2.031

6.  Headache associated with pituitary tumors.

Authors:  Jackson A Gondim; João Paulo Cavalcante de Almeida; Lucas Alverne Freitas de Albuquerque; Michele Schops; Erika Gomes; Tânia Ferraz
Journal:  J Headache Pain       Date:  2008-12-09       Impact factor: 7.277

7.  The volume of tumor mass and visual field defect in patients with pituitary macroadenoma.

Authors:  Jung Pil Lee; In Won Park; Yun Suk Chung
Journal:  Korean J Ophthalmol       Date:  2011-01-17

8.  The influence of pituitary adenoma size on vision and visual outcomes after trans-sphenoidal adenectomy: a report of 78 cases.

Authors:  Ren-Wen Ho; Hsiu-Mei Huang; Jih-Tsun Ho
Journal:  J Korean Neurosurg Soc       Date:  2015-01-31

9.  Demographic study of pituitary adenomas undergone trans-sphenoidal surgery in Loghman Hakim Hospital, Tehran, Iran 2001-2013.

Authors:  Farahnaz Bidari Zerehpoosh; Shahram Sabeti; Guive Sharifi; Hania Shakeri; Setareh Alipour; Farid Arman
Journal:  Indian J Endocrinol Metab       Date:  2015 Nov-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.